ArticleDiscover oncology2026
Radiogenomics deciphers tumor heterogeneity in hepatocellular carcinoma and combined hepatocellular-cholangiocarcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCombined hepatocellular cholangiocarcinoma (cHCC-CCA) is a highly heterogeneous cancer with limited knowledge of molecular features and prognosis. To compare the molecular features of cHCC-CCA with different subtypes of hepatocellular carcinoma (HCC) and to investigate the biological meanings of prognostic radiomic features in cHCC-CCA.
methodsWe performed an integrative analysis to investigate the heterogeneity of cHCC-CCA and HCC by combining transcriptomic and radiomic approaches. RNA sequencing revealed distinct transcriptomic profiles between cHCC-CCA and HCC. For radiomic analysis, an eight-feature radiomic signature was constructed using preoperative contrast-enhanced MRI to predict overall survival in cHCC-CCA, and its prognostic significance was validated in an external dataset. Furthermore, weighted gene co-expression network analysis was employed to correlate radiomic features with underlying biological pathways.
resultsLR-M subtype of cHCC-CCA exhibited more aggressive characteristics and immunosuppressive tumor microenvironment compared with LR-4/5 subtype, HCC with rim arterial-phase hyperenhancement (rim-APHE) and HCC without rim-APHE. The radiomic signature was correlated with overall survival (hazard ratio [HR], 5.47; 95% CI:2.08, 7.23, p = 0.006) in the cHCC-CCA validation cohort. Three types of prognostic radiomic features were correlated with distinct pathways: fatty acid metabolism, signaling pathways regulating pluripotency of stem cells and T cell receptor signaling pathway, respectively. Original_Glszm_GrayLevelNonUniformity might reflect the upregulation of fatty acid metabolism and immune suppression of cHCC-CCA.
conclusionsWe illustrated the heterogeneity of subtypes of HCC and cHCC-CCA, which provides insights into the differentiation of primary liver cancer. Correlation of prognostic radiomic features with transcriptome profiles in cHCC-CCA enables noninvasive evaluation of tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.